AI Diagnostics
Are you going to meet your AI doctor now? Await! It has arrived. But under caution. What is that? Should AI Diagnostics be allowed to make medical judgments on their own, without human oversight? Never! Self-Driving Even automobiles can crash. It doesn’t mean that we cannot look in. There are still positive points. Once, 17 doctors couldn’t diagnose a rare back pain. The child’s mom fed all details of the primary medical reports to ChatGPT as the last option. She was lucky enough! ChatGPT FOUND the real cause.
But our topic is about AI. Of course, AI uses are still in development mode. Do not forget that. There is a high chance that even though we can take “some” advantage, if you still believe in technology. Do you wanna see what is happening in the business field? Take a look here.
Cleerly for AI Diagnostics.
This solution produces diagnostic software that analyzes cardiac scans using artificial intelligence. It evaluates the amount and type of plaque in the heart’s arteries using images from coronary computed tomography angiography (CCTA). It is trained on more than 10 million scans from 40K patients.
When evaluating scans without AI support, clinical readers may overstate issues. Cleerly’s method identified 53% fewer serious stenoses (abnormal narrowing of passageways) than medical professionals in one study, eliminating the need for additional, unnecessary testing.
Additionally, the AI can identify problems that doctors might overlook. Conventional methods that merely evaluate symptoms or risk indicators categorize 70% of heart attack victims as “low-risk.” In December 2024, Cleerly completed a Series C extension, increasing the total amount of investment to $106 million.
For AI coronary plaque scanning, the AMA has released a new Category I CPT code, effective January 2026. This acknowledges the technology’s solid evidentiary base, opening the door for its wider availability under insurance plans.
Furthermore, AI shows promise across medical imaging, not just cardiac imaging. More than 1.4K “AI-enabled” medical devices have been authorized by the FDA, most of which are related to radiology.
By 2033, the AI healthcare imaging industry is projected to have grown from its current estimated $1.67 billion to $12.69 billion.
What does Cleerly do for the innovative energy?
Through its precision diagnostic solutions, Cleerly develops digital care for heart disease by enabling coronary artery disease phenotyping. In addition to enabling deep coronary phenotyping, Cleerly’s solutions incorporate capabilities that help clinicians, including general cardiologists and primary care physicians, understand the significance of the data without requiring advanced imaging expertise. To enhance health literacy and provide patients with information, it also incorporates interactive, customized, patient-facing tools. Lastly, quantitative techniques allow patients and their healthcare team to monitor changes in coronary artery disease over time.
“We’re not yet using advanced imaging to avoid the most prevalent cause of mortality, but it has been essential for years in recognizing and avoiding the most prevalent types of cancer. We employ lung CT scans, colonoscopies, and 3D mammograms to detect and prevent lung, breast, and colon cancer, but we haven’t had comparable tools for heart disease, the leading cause of death worldwide. Cleerly is bringing heart disease detection & prevention into the 21st century through artificial intelligence, continuously improved by our unparalleled volume of unique, accumulated clinical data.
What are the other options available for AI diagnostics?
For AI coronary plaque scanning, the AMA has released a new Category I CPT code, effective January 2026. This acknowledges the technology’s solid evidentiary base, opening the door for its wider availability under insurance plans.
Furthermore, AI shows promise in medical imaging overall, not just cardiac imaging. More than 1.4K “AI-enabled” medical devices have been authorized by the FDA, most of which are related to radiology. By 2033, the AI healthcare imaging industry is projected to have grown from its current estimated $1.67 billion to $12.69 billion. Among the startups in the field are ( we took Cleerly AI as the first option). So starting from the 2nd one…
2.0 Spectral AI.
Spectral AI develops wound imaging technology. According to recent research, its Deepview system was more than twice as effective as burn doctors at identifying non-healing tissue.
Is Spectral AI trustworthy for AI diagnostics?
Well, look at this analysis. Strong clinical trial outcomes and peer-reviewed publications confirm Spectral AI’s potential for AI diagnoses based on the information now available. However, the company is now pre-revenue, and its technology has not yet received FDA clearance for the USA market, which are important considerations when assessing its reliability.
Reasons for the Reliability of Spectral AI
The robustness of Spectral AI’s clinical proof and the official regulatory organizations’ acknowledgment of it are the main sources of its credibility.
Robust, Peer-Reviewed Clinical Outcomes:- The study’s publication in the journal Burns provides the strongest proof. A peer-reviewed medical journal’s achievement of 95.3% overall accuracy is a noteworthy scientific confirmation that its AI is capable of accurately determining burn depth & healing potential. This expands the body of evidence beyond business claims.
Outperformance of Clinical Experts:- Data from the company’s extensive Burn Validation Study, which was finished in early 2025, demonstrated that the AI greatly outperformed burn surgeons in a crucial area: detecting which tissue will not recover on its own (86.6% sensitivity for AI vs. 40.8% for clinicians). This implies that AI might be a useful tool to supplement specialized knowledge rather than to replace it.
Formal FDA Recognition:- The device’s “Breakthrough Device Designation” from the FDA is a powerful indication. This category is only granted to technologies that have the potential to provide a diagnosis or treatment for life-threatening illnesses that is better than what is currently available.
3.0 Lunit AI
40% of patients with breast cancer can receive an early diagnosis thanks to Lunit, an AI for cancer detection. From 2019 to 2025, revenue increased at a CAGR of 173%.
By looking at the trend, we can consider a few AI diagnostics options. Can Lunit AI be trusted? It depends. Such sensitive, important jobs cannot be replaced by AI. Would anyone feel at ease entrusting a robot with their entire life? Since human empathy and accountability cannot be programmed, that seems extremely implausible. AI, however, has the potential to significantly alter the medical industry. For instance, radiologists may diagnose illnesses from X-rays with the help of AI technologies like Lunit-Conquer Cancer. AI is capable of analyzing vast amounts of medical data, spotting trends, and even detecting illnesses that people might overlook but are nonetheless apparent in radiology reports, MRIs, and CT scans. even though progress will continue to be made. Since it can count small details that are occasionally overlooked in standard human diagnosis, I believe it is beneficial for patients.
Does it mean AI diagnostic Apps can fully replace Doctors?
Nope! The majority of diagnostic testing will still be required. AI may take over interpreting those tests and applying the interpretation to inform future management decisions.
Significantly more advanced tactile 3-D sensor capabilities would be required before AI could conduct a physical examination. Additionally, it would be necessary to incorporate live patient comments effectively.
Additionally, AI is still not very adept at capturing subtleties in patient interactions. A skilled doctor can typically tell when a patient is withholding information and knows how to bring it up gently. Computers are typically direct and literal.
Additionally, a competent doctor can identify when a patient is unlikely to adhere to treatment recommendations, explain why, and encourage the patient to at least attempt those recommendations before quitting. Alternatively, the doctor may be able to offer an option that the patient is more likely to follow. Computers often reduce problems to binary yes-or-no, all-or-none options; this approach is effective in certain situations but often fails in clinical practice.
Things to Take Into Account Before Assessing the Trustworthiness of AI diagnostics.
Despite the encouraging clinical results, there are important aspects that need to be carefully taken into account, particularly in relation to its present state of development, along with its financial situation.
Regulatory Status: Not currently approved: The DeepView® System’s primary drawback is that it is not currently a commercially available medical device in the US. The FDA has yet to make a final decision regarding its reliability as a diagnostic tool. The business anticipates hearing back about their application in early 2026.
Financial Health as Commercial Viability: Spectral AI’s financials reveal net losses, and the company is not yet profitable while it works to launch its first significant product. This is not out of the ordinary for a medical device company in the development stage, but it is a business risk unrelated to the therapeutic potential of the technology.
Forward-Looking Statements: The company makes “forward-looking statements” about its intentions and expectations in almost all of its communications, which are by their very nature ambiguous. Investors and prospective users need to differentiate these long-term goals from the verified outcomes of finished research.
Summary
From the standpoint of clinical data, AI diagnostics technology seems reliable, but the company is still in the pre-commercialization phase. The peer-reviewed research is encouraging for medical professionals, but FDA clearance is required for widespread clinical use. Strong clinical findings must be balanced against financial risks and regulatory approval uncertainties if you are an investor.
Read more on related topics here. Healthcare automating, Neural networks
